

Stereoselective synthesis of optically active bicyclic β -lactam carboxylic acids that target pilus biogenesis in pathogenic bacteria $\dagger$

Hans Emtenäs,^a Marcus Carlsson,^a Jerome S. Pinkner,^b Scott J. Hultgren^b and Fredrik Almqvist^{*a}

^a Organic Chemistry, Department of Chemistry, Umeå University, SE-901 87 Umeå, Sweden

^b Department of Molecular Microbiology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, USA. E-mail: fredrik.almqvist@chem.umu.se

Received 29th October 2002, Accepted 20th February 2003

First published as an Advance Article on the web 11th March 2003

Optically active bicyclic β -lactams were synthesized, starting from 2-H- Δ^2 -thiazolines and Meldrum's acid derivatives. Several methods to accomplish an ester hydrolysis without damaging the β -lactam framework were investigated. A rapid CsOH saponification of the β -lactam methyl esters was developed and protonation of the Cs-carboxylates by Amberlite (IR-120 H⁺) afforded a series of bicyclic β -lactam carboxylic acids. Moreover, a convenient method for the synthesis of 2-H- Δ^2 -thiazolinecarboxylic acid methyl ester **2** was developed. Bicyclic β -lactam carboxylic acids **7a–g** and aldehydes **4a–d** were screened for their affinity to the bacterial periplasmic chaperone PapD using a surface plasmon resonance technique. β -Lactams substituted with large acyl substituents showed better binding to the chaperone than the native C-terminal peptide PapG **8**, demonstrating that bicyclic β -lactams constitute a new class of potential bacterial chaperone inhibitors.

Introduction

β -Lactams have gained substantial interest in the scientific community not only due to their antibiotic properties^{1–3} but also as reactive intermediates and as starting materials in a wide range of synthetic settings.^{4,5} The heavy use of antibiotics during the second half of the last century has resulted in an increasing number of bacteria being resistant to the drugs available today.^{6,7} One way of overcoming this problem involves development of antibacterial agents against novel targets in the microorganism.⁸

A large number of infectious Gram negative bacteria produce pili, which are a family of extracellular, supramolecular protein organelles that mediate attachment to host tissue.⁹ Pilus assembly is performed by periplasmic chaperones that fold and transport the subunits to the outer cell membrane where they are incorporated into a growing pilus.¹⁰ Thus, if the chaperone-subunit complex can be prevented from being formed, colonization of host tissue cannot occur.^{11,12} Moreover, periplasmic chaperones constitute a highly conserved structure, which can be found in a large number of pathogenic bacteria such as *B. pertussis*, *S. typhimurium* and *H. influenzae* responsible for the diseases whooping cough, gastrointestinal disorder and meningitis respectively.^{9,13} In addition, the structures of the chaperone-subunit complexes are well studied and it has been shown, both by NMR^{14,15} and X-ray crystallography,^{16,17} that the pili-subunits bind to the chaperone by anchoring of the carboxy terminus to the side chains of Arg 8 and Lys 112. Previously, we reported a stereoselective synthesis of optically active β -lactams, which were designed to be a suitable scaffold for the development of compounds (termed pilicides) that inhibit pilus formation in uropathogenic *E. coli*.¹⁸ Bicyclic β -lactam methyl esters **3** were synthesized in yields as high as 93% by reacting the two key intermediates, the acyl Meldrum's acids **1** and 2-H- Δ^2 -thiazoline methyl ester **2** (Fig. 1). These esters could then be selectively reduced to the corresponding




Fig. 1 Original procedure for the formation of the β -lactam methyl esters **3** and their corresponding aldehydes **4**.

aldehydes **4** by DIBAL-H, which would have potential to form imines with Lys 112.¹⁸

The stereochemistry of the β -lactams synthesized by this method is different compared to the original penicillin's, thus having a chance to withstand enzymatic degradation by penicillin-resistant bacteria. Other compounds such as bicyclic 2-pyridinones **5** and amino acid derivatives **6** (Fig. 2) are known

$\dagger$ Electronic supplementary information (ESI) available: ¹³C NMR spectra of **7(a–g)**, **10–14**, **16(a and d)** and **17(a–b)**. See <http://www.rsc.org/suppdata/ob/b2/b210551a/>




Fig. 2 Bicyclic 2-pyridinone **5**, amino acid derivative **6** and the heptapeptide **8**, corresponding to the C-terminus of the pilus adhesion protein PapG, have shown chaperone binding and chaperone/subunit inhibitor activity.¹⁹ Novel bicyclic β -lactam carboxylic acids **7** targeted in this article are also designed to have corresponding biological activity.


to bind to chaperones as free carboxylic acids¹⁹ or as their corresponding Li-salts.²⁰ This article describes the synthesis of β -lactam carboxylic acids and the study of their binding affinity to the periplasmic chaperone PapD by the surface plasmon resonance technique. Moreover, a new practical and efficient procedure for the synthesis of the important intermediate, 2-H- Δ^2 -thiazolinecarboxylic acid methyl ester **2**, was developed.

Results and discussion

The first approach was to synthesize the desired β -lactam carboxylic acids from the 2-H- Δ^2 -thiazoline carboxylic acid and a Meldrum's acid derivative. Following a procedure developed by Walker,²¹ the Δ^2 -thiazoline carboxylic acid hydrochloride


was constructed. Unfortunately, it turned out to be almost insoluble in solvents suitable for the following β -lactam synthesis (benzene or 1,2-dichloroethane), and no β -lactam was formed. Therefore the strategy was to synthesize the β -lactam esters, which then have to be hydrolyzed to generate the carboxylic acids. Thus, with the methyl esters **3** in hand,¹⁸ (Fig. 1) attempts to hydrolyze **3a** by mild saponification (e.g. K_2CO_3 in MeOH–H₂O 9 : 1) gave in the best case a 1 : 1 mixture of starting material and product, which was difficult to purify. Prolonged reaction time resulted in decomposition of the β -lactam ring. In addition, attempts to hydrolyze **3a** with $(Bu_3Sn)_2O$ in benzene,^{22,23} or **3c** with pig liver esterase^{24,25} were also unsuccessful. Tsuji *et al.* developed a method for the hydrolysis of benzyl esters of cephalosporin analogs using $AlCl_3$,²⁶ which seemed attractive. Thus, the cysteine benzyl ester was prepared²⁷ and the 2-H- Δ^2 -thiazoline was synthesized based on the same protocol as for the methyl ester²⁸ giving the benzyl ester **10** in 37% overall yield in three steps (Scheme 1). Allowing **10** to react with the Meldrum's acid derivative **1c** gave the β -lactam **11** in 58% yield but all attempts of using $AlCl_3$,²⁶ $TiCl_4$ ²⁶ or hydrogenation with Pd/C²⁹ to cleave the benzyl-ester were unsuccessful.

p-Nitrobenzyl (PNB) esters have shown to be hydrolyzable by using Zn in a phosphate buffer.³⁰ Consequently, the orthogonally protected cysteine-PNB ester **12** was synthesized (Scheme 1). After simultaneous acidic removal of the *N*- and *S*-protecting groups, the corresponding cysteine-PNB ester was converted to the 2-H- Δ^2 -thiazoline-PNB ester **13** in 36% overall yield (from **12** in three steps) and reaction of this intermediate with the Meldrum's acid derivative **1c** gave the β -lactam-PNB ester **14** in 63% yield (Scheme 1). However, this ester also proved to be difficult to hydrolyze using procedures such as Zn in phosphate buffer, Zn in HCl (6 M),²⁷ Na_2S in THF–H₂O³¹ or hydrogenation with different catalysts (e.g. Pd/C or PtO_2). At this stage, to be able to find a productive route to the desired β -lactam carboxylic acids, the need for a practical procedure to synthesize different 2-H- Δ^2 -thiazoline esters became critical. In the literature there are a wide range of mild methods for the hydrolysis of different carboxylic esters³² and the strategy to prepare cysteine esters *via* the previous two routes was time consuming. Thus, we wanted to prepare the 2-H- Δ^2 -thiazoline **2** on a large scale and then perform transesterifications to the desired esters. Scaling up the previous method²⁸ was not straightforward since flash chromatography had to be conducted to remove unreacted formylated amino acid and the 2-Me- Δ^2 -thiazoline methyl ester, which occasionally appeared in the synthesis. By using a modified procedure, previously used to prepare optically active 2-oxazolines,³³ the




Scheme 1 Two different routes to furnish the benzyl- or the *p*-nitrobenzyl ester **11** and **14** respectively.

optically active 2-H- Δ^2 -thiazoline methyl ester **2** could be prepared in quantitative yield without the need for chromatography (Scheme 2). The enantiomeric ratio (er) was established by ^1H NMR (in the presence of $\text{Eu}(\text{hfc})_3$) to be 9 : 1 (corresponding to 80% ee), which also is an improvement compared to the former procedure.²⁸



Scheme 2 A convenient method for the synthesis of optically active 2-H- Δ^2 -thiazoline methyl ester **2**.

The transesterification was performed by first generating the Cs-carboxylate ($\pm$)-**15** via a CsOH (0.1 M aq.) saponification. Thereafter, ($\pm$)-**15** was sequentially alkylated to furnish the new esters ($\pm$)-**16** in moderate to excellent overall yields 57–98% (Scheme 3).



Scheme 3 Synthesis of different 2-H- Δ^2 -thiazoline esters ($\pm$)-**16** and their corresponding β -lactam esters ($\pm$)-**17a** and ($\pm$)-**17b**.

Thus, with these new 2-H- Δ^2 -thiazolines in hand the corresponding heptyl and propargyl β -lactam esters ($\pm$)-**17a** and ($\pm$)-**17b** were synthesized in 70 and 91% yields respectively. Others had shown that many heptyl esters can be easily hydrolyzed by enzymes under relatively mild conditions (acetone–phosphate buffer pH = 7 at 37 °C)^{34–36} but treating the β -lactam heptyl ester ($\pm$)-**17a** with a variety of lipases gave no desired carboxylic acid. Another mild alternative was to use the propargyl ester, which should be possible to hydrolyze by treatment with $\text{Co}_2(\text{CO})_8$ and TFA in CH_2Cl_2 .³⁷ Disappointingly, the propargylic ester ($\pm$)-**17b** could not be hydrolysed under these conditions and increasing the temperature or the amount of $\text{Co}_2(\text{CO})_8$ gave no improvement and most of the starting material could be recovered.

Since the CsOH hydrolysis was so successful in the 2-H- Δ^2 -thiazoline case, we anticipated that it could be fruitful also for the β -lactam methyl esters provided that the reaction time could be kept short. Thus, 1 eq. of aqueous CsOH (0.1 M) was added to a solution of the β -lactam methyl ester **3** in MeOH and the resulting solution was immediately concentrated under reduced pressure. After being co-concentrated twice from dry EtOH followed by dilution in dry EtOH, the β -lactam carboxylic acids were obtained by protonation with Amberlite (IR-120 H^+) (Fig. 3).





Fig. 3 Epimerization of the α -carbon would result in the diastereomers **18**.

Although this method had caused racemization in the hydrolysis of **2**, the ^1H NMR spectrum of the crude product showed no undesired diastereomers **18** and the β -lactam moiety was still intact. Purification by flash chromatography turned out to be difficult and gave decomposition of the β -lactam framework. Fortunately, trituration with acetone resulted in precipitation of the β -lactam carboxylic acids. A series of optically active bicyclic β -lactam carboxylic acids **7a–g** were synthesized with this method, all in excellent yields >98% except for the pentyl derivative **7f**, which was problematic to triturate resulting in a moderate yield of 60% (Scheme 4).



Scheme 4 Rapid saponification of the methyl esters **3** with CsOH followed by protonation to give the β -lactam carboxylic acids **7**.


Biological evaluation

The β -lactam carboxylic acids **7(a–g)** and the β -lactam aldehydes **4(a–d)** were tested for their capability of binding to the periplasmic chaperone PapD with surface plasmon resonance on a Biacore 3000 instrument. This method has earlier proven to be a good screening device for pilicides, since the chaperone binding properties have been shown to correlate to the capability of disrupting a preformed chaperone-subunit complex.¹⁹ Normalized responses were calculated using the 2-pyridinone **5** as reference since this was the most efficient pilicide in the earlier study.¹⁹ In this screening β -lactams with a fairly large acyl substituent showed substantial binding to the chaperone PapD (Table 1). Interestingly, this was true also for the aldehyde derivatives **4(a–d)**. The aldehydes came off the chaperone as easily as the carboxylic acids in the washing step, which indicates that no imine was formed. Although not as good binders as the reference compound **5**, **7(a–g)** still bound better than the native C-terminal peptide PapG **7** which previously had showed inhibition of PapD in an ELISA.¹⁶ Furthermore, **8(e–f)** showed almost the same affinity as the peptide PapG but the β -lactam bearing a small methyl substituent **7g** showed very weak binding.

Conclusions

A new practical synthesis of the key building block 2-H- Δ^2 -thiazoline methyl ester **2** was developed which gave excellent yield and limited racemization. Then, a series of β -lactam esters was synthesized in good to excellent yields and different methods for ester hydrolysis were investigated. Among these the only fruitful protocol was a very fast saponification procedure, developed in our laboratory, resulting in a series of optically active β -lactam carboxylic acids. A surface plasmon resonance

Table 1 Affinities of compounds **4(a–d)** and **7(a–g)** for the PapD chaperone. Peptide PapG **8** and 2-pyridinone **5** are included for comparison



Compound	R ¹	R ²	Norm. response for PapD ^a
7a	Ph	CO ₂ H	35
7b	1-Naphthyl	CO ₂ H	29
7c	CH ₂ -1-naphthyl	CO ₂ H	35
7d	CH ₂ -2-naphthyl	CO ₂ H	46
7e	Cyclohexyl	CO ₂ H	18
7f	<i>n</i> -Pentyl	CO ₂ H	22
7g	Me	CO ₂ H	2
4a	Ph	CHO	31
4b	1-Naphthyl	CHO	21
4c	CH ₂ -1-naphthyl	CHO	34
4d	CH ₂ -2-naphthyl	CHO	25
5	—	—	100
8	—	—	25

^a Determined by surface plasmon resonance at a fixed pilicide concentration (30 μ M) using a Biacore 3000 instrument. The normalized responses were calculated using **5** as standard (100 % norm. response) and all compounds were tested in triplicate in random order.

screening for the capability of binding to a periplasmic chaperone, PapD, revealed that β -lactams substituted with fairly large acyl substituents bound stronger to the chaperone than the native C-terminal peptide PapG **8**. Consequently, the bicyclic β -lactams can be considered as a new family with chaperone binding properties and they will be further evaluated as pilicides in the near future.

Experimental

General

All reactions were carried out under an inert atmosphere with dry solvents under anhydrous conditions, unless otherwise stated. 1,2-Dichloroethane and CH₂Cl₂ were distilled from calcium hydride (and THF from potassium, respectively). Benzene and toluene were distilled from sodium. TLC was performed on Silica Gel 60 F₂₅₄ (Merck) with detection by UV light and staining with a solution of anisaldehyde (26 mL), glacial acetic acid (11 mL) and concentrated sulfuric acid (35 mL) in 95% ethanol (960 mL). Flash column chromatography (eluent given in brackets) was performed on silica gel (Matrix, 60 Å, 35–70 μ m, Grace Amicon). Centrifugal preparative TLC was performed using rotors coated with silica gel 60 PF₂₅₄ containing CaSO₄ (Merck). The moving bands were visualized using UV light. The ¹H and ¹³C NMR spectra were recorded on a Bruker DRX-400 for solutions in CDCl₃ [residual CHCl₃ (δ_{H} 7.26 ppm) or CDCl₃ (δ_{C} 77.0 ppm) as internal standard] or in DMSO-d₆ [residual DMSO-d₅ (δ_{H} 2.50 ppm) or DMSO-d₆ (δ_{C} 40.0 ppm) as internal standard] at 298 K. First-order chemical shifts and coupling constants were obtained from one-dimensional spectra. IR spectra were recorded on an ATI Mattson Genesis Series FTIRTM spectrometer. Optical rotations were measured with a Perkin-Elmer 343 polarimeter and are given in 10^{−1} deg cm² g^{−1}. High resolution mass spectra were recorded on a JEOL SX102 A mass spectrometer. Ions for FABMS were produced by a beam of Xenon atoms (6 keV) from a matrix of glycerol and thio-glycerol. Mass spectra on the β -lactam carboxylic acids **7** were recorded on a Waters micromassZQ using positive electrospray (ES+).

(4R)-4,5-Dihydrothiazole-4-carboxylic acid methyl ester (2)

TEA (2.9 mL, 20.6 mmol) was added dropwise to a suspension of L-cystine methyl ester hydrochloride (4000 mg, 23.3 mmol) in dry 1,2-dichloroethane (23 mL) at 0 °C. After stirring for 10 min the mixture was diluted with 1,2-dichloroethane (30 mL) and triethyl orthoformate (5.7 mL, 34.6 mmol) was added. After refluxing the mixture using a Soxhlet with molecular sieves 4 Å for 2 h a catalytic amount of PTSA was added, and the mixture was refluxed for another 18 h before reaching rt. Toluene was added and the mixture was cooled to −18 °C. Precipitated TEA–HCl was filtered off and the filtrate was concentrated yielding **2** as an oil in quantitative yield. [α]_D²⁰ 130 (*c* 1.18, CHCl₃); IR (neat) 1741, 1572, 1437, 1340, 1219, 1039, 810 cm^{−1}; ¹H NMR (400 MHz, CDCl₃) δ 7.99 (d, *J* = 2.29 Hz, 1H), 5.01–5.11 (m, 1H), 3.78 (s, 3H), 3.39–3.53 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 170.9, 159.6, 77.7, 52.9, 33.3; HRMS (EI+) Calcd. for C₅H₇NO₂S: 145.0197 Obsd. 145.0186.

β -Lactam methyl esters **3a–g** and β -lactam aldehydes **4a–d**

Prepared according to published procedures.¹⁸

(4R)-4,5-Dihydrothiazole-4-carboxylic acid benzyl ester (10)

To the suspension of L-cystine dibenzyl ester di-tosylate (1640 mg, 2.14 mmol) in dioxane (7.0 mL) and conc. HCl (1.0 mL) was added zinc dust (600 mg, 9.17 mmol) in many portions over a period of 15 minutes with vigorous stirring. After stirring at rt for 1.5 h, undissolved zinc was filtered off and washed with dioxane and the filtrate was concentrated. The residue was freeze-dried from water. The residue was dissolved in pyridine (10 mL) and a previously prepared solution of acetic anhydride (1.05 eq.) and formic acid (1.2 eq.) was added. After stirring for 2 h at rt the solution was concentrated. The residue was dissolved in CHCl₃ and the pH was adjusted to neutral with 6 M HCl and the solution was co-concentrated from CHCl₃ (3 $\times$). The residue was suspended in benzene (100 mL), a catalytic amount of PTSA was added, and the solution was refluxed overnight using a Dean Stark apparatus. The organic phase was washed with saturated NaHCO₃, water and brine. The water phase was extracted twice with CH₂Cl₂ and the combined organic extracts were dried with Na₂SO₄, filtered and concentrated. Flash chromatography (heptane–ethyl acetate 5 : 1–1 : 1) gave **10** (350 mg, 37%). [α]_D²⁰ 16 (*c* 4.40, CHCl₃); IR (neat) 1747, 1662, 1513, 1392, 1344, 1172, 964, 775, 734 cm^{−1}; ¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, *J* = 2.38 Hz, 1H), 7.31–7.41 (m, 5H), 5.19–5.30 (m, 2H), 5.10–5.17 (m, 1H), 3.42–3.56 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 170.1, 159.6, 135.2, 128.5, 128.4, 128.2, 77.7, 67.3, 33.2 HRMS (FAB+) Calcd. For (M + 1) C₁₁H₁₂NO₂S: 222.0589 Obsd. 222.0591.

Boc-Cys(Trt)-PNB, (12)

Boc-Cys(Trt)-CO₂H (6000 mg, 12.9 mmol) was dissolved in 80% aqueous EtOH (100 mL), and the pH was adjusted to pH 10 with 30% aqueous Cs₂CO₃, concentrated at reduced pressure, then diluted with EtOH (absolute), and concentrated at high vacuum. The resulting powder was dissolved in DMF (50 mL) and cooled to 0 °C, after which 4-nitrobenzyl bromide (3300 mg, 15.3 mmol) was added dropwise. After 12 h at rt the reaction mixture was diluted with water and extracted with Et₂O. The organic phase was dried with Na₂SO₄, filtered and concentrated. Flash chromatography (heptane–ethyl acetate 8 : 2–7 : 3) gave **12** (7900 mg, 100%). [α]_D²⁰ 11 (*c* 1.7, CHCl₃); IR (neat) 3374, 2966, 1745, 1712, 1606, 1511, 1444, 1346, 1261, 1157, 1012, 844, 738, 698 cm^{−1}; ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 8.69 Hz, 2H), 7.46 (d, *J* = 8.69 Hz, 2H), 7.33–7.38 (m, 5H), 7.19–7.30 (m, 10H), 5.15–5.30 (m, 2H), 5.04 (d, *J* = 8.23 Hz, 1H), 4.26–4.38 (m, 1H), 2.52–2.73 (m, 2H), 1.43 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 170.5, 155.0, 147.7,

144.1, 142.5, 129.4, 128.4, 128.0, 127.0, 123.7, 80.2, 66.9, 65.6, 52.6, 34.0, 28.3 HRMS (FAB+) Calcd. for (M + Na) C₃₄H₃₄N₂O₆SNa: 621.2035 Obsd. 621.2030.

(4R)-4,5-Dihydrothiazole-4-carboxylic acid 4-nitrobenzyl ester (13)

A solution of TFA–H₂O–thioanisole–ethanedithiol 175 : 10 : 10 : 5 (200 mL) was added to **12** (7900 mg, 13.2 mmol) and after stirring for 3 h, AcOH (100 mL) was added and the solution was concentrated. To the residue was added AcOH (100 mL) and the white precipitate was filtrated off. The filtrate was concentrated and the residue was triturated with Et₂O which gave a solid, crude product which was dissolved in a solution of AcOH and water and freeze-dried yielding Cys-PNB (3200 mg) as a powder which was used in the next step without further purification. To a solution of Cys-PNB (1450 mg) in pyridine (7.5 mL) was added a previously prepared solution of acetic anhydride (1.05 eq.) and formic acid (1.2 eq.) and after stirring for 2 h at room temperature the solution was concentrated. The residue was dissolved in CHCl₃ and pH was adjusted to neutral with 6 M HCl and the solution was co-concentrated from CHCl₃ (3×). The residue was suspended in benzene (180 mL), a catalytic amount of PTSA was added, and the solution was refluxed overnight using a Dean Stark apparatus. The organic phase was washed with saturated NaHCO₃, water and brine. The water phase was extracted twice with CH₂Cl₂ and the combined organic extracts were dried with Na₂SO₄, filtered and concentrated. Flash chromatography (heptane–ethyl acetate 3 : 1–1 : 2) gave **13** (550 mg, 35%). [α]_D²⁰ 43 (c 1.40 CHCl₃); IR (neat) 3066, 1749, 1680, 1602, 1512, 1342, 1315, 1180 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, *J* = 8.60 Hz, 2H), 8.06 (d, *J* = 2.38 Hz, 1H), 7.54 (d, *J* = 8.78 Hz), 5.33 (s, 1H), 5.15–5.22 (m, 1H), 3.45–3.60 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 170.1, 160.2, 147.9, 142.5, 128.6, 124.0, 77.7, 65.9, 33.3; HRMS (CI+) Calcd. for C₁₁H₁₁N₂O₄S: 267.0440 Obsd. 267.0443.

4,5-Dihydrothiazole-4-carboxylic acid heptyl ester ((±)-16a)

Aqueous CsOH (0.1 M, 68.5 mL) was added dropwise to a stirred solution of thiazoline methyl ester **2** (1000 mg, 6.85 mmol) in MeOH (200 mL) at rt. The mixture was immediately concentrated and the residue was co-concentrated four times from dry EtOH giving the thiazoline Cs-salt as a white foam. A solution of heptyl bromide (1.50 mL, 9.50 mmol) in DMF (6 mL) was added dropwise to a solution of the Cs-salt (±)-**15** (1390 mg, 5.28 mmol) in DMF (16 mL) at 0 °C. After stirring for 2 h the cooling bath was removed and the reaction was allowed to reach rt overnight. The reaction mixture was diluted with Et₂O and washed with ice cooled water (7×) and the organic extract was dried with Na₂SO₄, filtered and concentrated. Flash chromatography (heptane–ethyl acetate 1 : 1), spinning centrifugal preparative TLC (heptane–ethyl acetate 3 : 7), spinning centrifugal preparative TLC (heptane–ethyl acetate 7 : 3) gave (±)-**16a** (692 mg, 57%) as an oil. [α]_D²⁰ 0 (c 1.05 CHCl₃); IR (neat) 2954, 2929, 2858, 2360, 1741, 1571, 1465, 1186 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, *J* = 2.2 Hz, 1H), 5.09 (dt, *J* = 9.51, 2.38 Hz, 1H), 4.15–4.21 (m, 2H), 3.43–3.55 (m, 2H), 1.61–1.71 (m, 2H), 1.18–1.38 (m, 10H), 0.81–0.89 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.5, 159.7, 77.6, 66.0, 33.2, 31.6, 28.8, 28.4, 25.6, 22.4, 14.0; HRMS (EI+) Calcd. for C₁₁H₁₉NO₂S: 229.1136, Obsd. 229.11337.

4,5-Dihydrothiazole-4-carboxylic acid benzyl ester ((±)-16b)

By following the procedure described for the preparation of (±)-**16a** from (±)-**15**, (±)-**15** (188 mg, 1.30 mmol) and benzyl bromide (400 mg, 2.33 mmol) gave (±)-**16b** (180 mg, 62%) as an oil. [α]_D²⁰ 0 (c 1.00, CHCl₃), all spectroscopic data were in agreement with **10**.

4,5-Dihydrothiazole-4-carboxylic acid 4-nitrobenzyl ester ((±)-16c)

By following the procedure described for the preparation of (±)-**16a** from (±)-**15**, (±)-**15** (188 mg, 1.30 mmol) and 4-nitrobenzyl bromide (504 mg, 2.33 mmol) gave (±)-**16c** (240 mg, 70%) as a white powder. [α]_D²⁰ 0 (c 1.23, CHCl₃), all spectroscopic data were in agreement with **13**.

4,5-Dihydrothiazole-4-carboxylic acid prop-2-ynyl ester ((±)-16d)

By following the procedure described for the preparation of (±)-**16a** from (±)-**15**, (±)-**15** (800 mg, 3.04 mmol) and propargyl bromide (0.60 mL, 5.55 mmol) gave (±)-**16d** (504 mg, 98%) as an oil. [α]_D²⁰ 0 (c 0.92, CHCl₃); IR (neat) 3282, 1745, 1570, 1176, 1038, 810 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, 2.47 Hz, 1H), 5.11–5.18 (m, 1H), 4.80 (dq, *J* = 15.55, 2.47 Hz, 2H), 3.46–3.58 (m, 2H), 2.51 (t, *J* = 2.38 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 169.7, 160.1, 77.6, 77.3, 75.7, 53.2, 33.3; HRMS (EI+) Calcd. for C₇H₇NO₂S: 169.07975 Obsd. 169.0274.

6-(2-Naphthalen-1-ylacetyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylic acid heptyl ester ((±)-17a)

By following the published procedure described for the preparation of **3**,¹⁸ (±)-**16a** (810 mg, 3.53 mmol) and **1c** (1440 mg, 4.59 mmol) gave (±)-**17a** (1100 mg, 70%) as a foam. [α]_D²⁰ 0 (c 1.0, CHCl₃); IR (neat) 2972, 2656, 1741, 1676, 1402, 1199, 968 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.88 (t, *J* = 6.95 Hz, 2H), 7.81 (d, *J* = 8.14 Hz, 1H), 7.34–7.56 (m, 4H), 6.54 (s, 1H), 5.26 (d, *J* = 6.31 Hz, 1H), 5.10 (s, 1H), 4.14 (s, *J* = 6.68 Hz, 2H), 4.01 (s, 1H), 3.46–3.53 (m, 1H), 3.21 (d, *J* = 11.16 Hz, 1H), 1.57–1.67 (m, 2H), 1.20–1.37 (m, 10H), 0.84–0.92 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.1, 168.8, 160.7, 133.9, 131.8, 130.5, 128.8, 128.3, 128.1, 126.5, 125.9, 125.4, 123.4, 101.2, 94.1, 66.3, 60.8, 36.7, 32.0, 31.6, 28.7, 28.4, 25.6, 22.5, 14.0; HRMS (EI+) Calcd. for C₂₅H₂₉NO₄S: 439.18173 Obsd. 440.18897.

6-(2-Naphthalen-1-ylacetyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylic acid prop-2-ynyl ester ((±)-17b)

By following the published procedure described for the preparation of **3**,¹⁸ (±)-**16d** (340 mg, 2.01 mmol) and **1c** (816 mg, 2.61 mmol) gave (±)-**17b** (693 mg, 91%). [α]_D²⁰ 0 (c 1.05, CHCl₃); IR (neat) 3288, 1753, 1666, 1398, 1184, 968, 752 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.78–7.91 (m, 3H), 7.34–7.57 (m, 4H), 6.57 (s, 1H), 5.30 (d, *J* = 6.31 Hz, 1H), 5.11 (s, 1H), 4.74 (d, *J* = 2.38 Hz, 2H), 4.01 (s, 2H), 3.52 (dd, *J* = 11.71, 6.40 Hz, 1H), 3.25 (d, *J* = 11.07 Hz, 1H), 2.49 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 169.2, 168.5, 160.9, 134.0, 131.9, 130.6, 129.0, 128.5, 128.2, 126.7, 126.0, 125.6, 123.6, 101.2, 94.2, 76.8, 76.0, 60.8, 53.6, 36.9, 31.9; HRMS (EI+) Calcd. for C₂₁H₁₇NO₄S 379.0900 Obsd. 379.0962.

(2R,5S,6R)-6-(Naphthalen-1-ylacetyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid benzyl ester (11)

By following the published procedure described for the preparation of **3**,¹⁸ **10** (536 mg, 2.42 mmol) and **1c** (904 mg, 2.89 mmol) gave **11** (606 mg, 58%). [α]_D²⁰ 7 (c 0.70, CHCl₃); IR (neat) 2973, 2900, 1739, 1662, 1515, 1394, 1180, 1066, 962, 773, 732, 694 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.78–7.92 (m, 3H), 7.28–7.57 (m, 9H), 6.55 (s, 1H), 5.32 (d, *J* = 6.22 Hz, 1H), 5.18 (s, 2H), 5.09 (s, 1H), 4.00 (s, 2H), 3.49 (dd, *J* = 11.25, 6.22 Hz, 1H), 3.23 (d, *J* = 11.25 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 169.00, 168.98, 160.8, 135.0, 133.9, 131.8, 130.5, 128.9, 128.6, 128.5, 128.4, 128.2, 128.1, 126.5, 125.9, 125.5, 123.5, 101.2, 94.1, 67.8, 60.9, 36.8, 31.9; HRMS (FAB+) Calcd. for (M + 1) C₂₅H₂₂NO₄S 432.1270 Obsd. 432.1270.

(2R,5S,6R)-6-(Naphthalen-1-ylacetyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4-nitrobenzyl ester (14)

By following the published procedure described for the preparation of **3**,¹⁸ **13** (1060 mg, 3.95 mmol) and **1c** (1570 mg, 5.03 mmol) gave **14** (1200 mg, 63%). $[\alpha]_{\text{D}}^{20}$ 8 (c 0.60, CHCl₃); IR (neat) 3363, 2971, 2902, 1513, 1392, 1342, 1249, 1056, 734, 696 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, *J* = 8.69 Hz, 2H), 7.85–7.91 (m, 2H), 7.82 (d, *J* = 8.14 Hz, 1H), 7.40–7.56 (m, 5H), 7.37 (d, *J* = 6.31 Hz, 1H), 6.52 (s, 1H), 5.34 (d, *J* = 6.22 Hz, 1H), 5.22–5.32 (m, 2H), 5.11 (s, 1H), 4.02 (s, 2H), 3.54 (dd, *J* = 11.25, 6.22 Hz, 1H), 3.25 (d, *J* = 11.25 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 169.3, 168.9, 160.8, 147.8, 142.2, 133.9, 131.8, 130.4, 128.9, 128.4, 128.2, 126.6, 125.9, 125.5, 123.9, 123.4, 101.1, 94.0, 66.1, 60.8, 36.8, 31.9; HRMS (FAB+) Calcd. for (M + 1) C₂₅H₂₁N₂O₆S 477.1120 Obsd. 477.1120.

(2R,5S,6R)-6-Benzoyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (7a)

Aqueous CsOH (0.1 M, 10 mL) was added to a stirred solution of β -lactam methyl ester **3a** (300 mg, 1.03 mmol) in MeOH (40 mL) at room temperature and the solution was immediately concentrated. The residue was co-concentrated twice from dry EtOH giving a yellow oil. The resulting yellow oil was dissolved in EtOH and pH was adjusted to pH = 4 with Amberlite (IR-120 H⁺). The amberlyst was filtrated off and the filtrate was concentrated and the residue was triturated with acetone to give **7a** as a powder in quantitative yield. $[\alpha]_{\text{D}}^{20}$ 57 (c 1.48, DMSO); IR (neat) 3365, 1639, 1593, 1408, 1373, 1273 cm⁻¹; ¹H NMR (400 MHz, DMSO-d₆) δ 7.72–7.77 (m, 2H), 7.42–7.52 (m, 3H), 6.63 (s, 1H), 6.05 (s, 1H), 4.73 (d, *J* = 6.10 Hz, 1H), 3.28–3.34 (m, 1H), 3.19 (d, *J* = 9.80 Hz, 1H); ¹³C NMR (100 MHz, DMSO-d₆) δ 170.3, 162.3, 160.9, 131.7, 129.3, 126.7, 99.0, 95.4, 63.6, 33.3; MS (ES+) Calcd. for (M + 1) C₁₃H₁₂NO₄S: 278.05 Obsd. 277.93.

(2R,5S,6R)-6-Naphthalenyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (7b)

Compound **7b** was prepared from **3b** (300 mg, 0.88 mmol) as described above for the synthesis of **7a** from **3a**. After trituration with acetone **7b** was obtained as a powder in quantitative yield. $[\alpha]_{\text{D}}^{20}$ 16 (c 0.9, DMSO); IR (neat) 1563, 1508, 1338 cm⁻¹; ¹H NMR (400 MHz, DMSO-d₆) δ 7.96–8.18 (m, 3H), 7.51–7.73 (m, 4H), 6.94 (s, 1H), 5.7 (s, 1H), 4.74 (d, *J* = 5.85 Hz, 1H), 3.17–3.37 (m, 2H); ¹³C NMR (100 MHz, DMSO-d₆) δ 170.1, 164.0, 160.6, 133.7, 131.6, 130.6, 130.6, 129.3, 128.6, 127.8, 126.9, 125.7, 125.5, 104.3, 95.6, 63.1, 33.4; MS (ES+) Calcd. for (M + 1) C₁₈H₁₆NO₄S: 328.06 Obsd. 327.88.

(2R,5S,6R)-6-(Naphthalen-1-ylacetyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (7c)

Compound **7c** was prepared from **3c** (300 mg, 0.84 mmol) as described above for the synthesis of **7a** from **3a**. After trituration with acetone **7c** was obtained as a powder in quantitative yield. $[\alpha]_{\text{D}}^{20}$ -1 (c 0.1, DMSO); IR (neat) 3313br, 3056, 2923, 1714, 1596, 1373, 1095, 779 cm⁻¹; ¹H NMR (400 MHz, DMSO-d₆) δ 8.06 (d, *J* = 8.13 Hz, 1H), 7.83–7.98 (m, 2H), 7.41–7.61 (m, 4H), 6.51 (s, 1H), 5.01 (s, 1H), 4.71 (d, *J* = 6.73 Hz, 1H), 3.99–4.14 (m, 2H), 3.22–3.29 (m, 1H), 3.16 (d, *J* = 10.27 Hz, 1H); ¹³C NMR (100 MHz, DMSO-d₆) δ 170.8, 167.9, 160.5, 133.9, 132.2, 132.0, 129.0, 128.3, 128.2, 126.9, 126.4, 126.2, 124.5, 101.5, 95.0, 62.9, 36.2, 32.9; MS (ES+) Calcd. for (M + 1) C₁₈H₁₆NO₄S: 342.08 Obsd. 341.86.

(2R,5S,6R)-6-(Naphthalen-2-ylacetyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (7d)

Compound **7d** was prepared from **3d** (200 mg, 0.56 mmol) as described above for the synthesis of **7a** from **3a**. After trituration with acetone **7d** was obtained as a powder in quantitative

yield. $[\alpha]_{\text{D}}^{20}$ 1 (c 0.2, DMSO); IR (neat) 2987, 2902, 1708, 1629, 1394, 1220, 1058, 968, 757 cm⁻¹; ¹H NMR (400 MHz, DMSO-d₆) δ 7.72–7.94 (m, 4H), 7.34–7.53 (m, 3H), 6.47 (s, 1H), 5.24 (s, 1H), 4.71 (d, *J* = 5.35 Hz, 1H), 3.73 (s, 2H), 3.09–3.27 (m, 2H); ¹³C NMR (100 MHz, DMSO-d₆) δ 170.9, 167.7, 160.6, 134.2, 133.6, 132.5, 128.6, 128.1, 128.0 (2 $\times$), 127.9, 126.8, 126.4, 101.7, 63.1, 95.0, 39.1, 32.9; MS (ES+) Calcd. for (M + 1) C₁₈H₁₆NO₄S: 342.08 Obsd. 341.86.

(2R,5S,6R)-6-Cyclohexanecarbonyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (7e)

Compound **7e** was prepared from **3e** (130 mg, 0.44 mmol) as described above for the synthesis of **7a** from **3a**. After trituration with acetone **7e** was obtained as a powder (121 mg, 98%). $[\alpha]_{\text{D}}^{20}$ 27 (c 0.95, DMSO); IR (neat) 3319, 2927, 2852, 1647, 1595, 1414, 1371, 960, 752 cm⁻¹; ¹H NMR (400 MHz, DMSO-d₆) δ 6.40 (s, 1H), 5.14 (s, 1H), 4.67 (d, *J* = 6.13 Hz, 1H), 3.21–3.27 (m, 1H), 3.10–3.16 (m, 1H), 2.07–2.17 (m, 1H), 1.59–1.80 (m, 5H), 1.11–1.28 (m, 5H); ¹³C NMR (100 MHz, DMSO-d₆) δ 172.4, 170.5, 160.8, 98.5, 94.8, 63.1, 41.2, 33.0, 30.2, 30.0, 25.9, 25.8, 25.7; MS (ES+) Calcd. for (M + 1) C₁₃H₁₈NO₄S: 284.10 Obsd. 283.95.

(2R,5S,6R)-6-Hexanoyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (7f)

Compound **7f** was prepared from **3f** (160 mg, 0.56 mmol) as described above for the synthesis of **7a** from **3a**. After trituration with acetone **7f** was obtained as a powder (91 mg, 60%). $[\alpha]_{\text{D}}^{20}$ 13 (c 0.36, DMSO); IR (neat) 3278, 2924, 2854, 1645, 1593, 1414, 1373, 1273, 968 cm⁻¹; ¹H NMR (400 MHz, DMSO-d₆) δ 6.50 (s, 1H), 5.28 (s, 1H), 5.00 (d, *J* = 6.40 Hz, 1H), 3.41 (dd, *J* = 10.98, 6.40 Hz, 1H), 3.17 (d, *J* = 10.98 Hz, 1H), 2.21 (t, *J* = 7.50 Hz, 2H), 1.42–1.50 (m, 2H), 1.20–1.31 (m, 4H), 0.83–0.89 (t, *J* = 6.68 Hz, 3H); ¹³C NMR (100 MHz, DMSO-d₆) δ 171.2, 170.1, 160.6, 99.9, 94.3, 61.4, 32.7, 32.2, 31.0, 25.8, 22.2, 14.3; MS (ES+) Calcd. for (M + 1) C₁₂H₁₈NO₄S: 272.10 Obsd. 272.07.

(2R,5S,6R)-6-Acetyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (7g)

Compound **7g** was prepared from **3g** (190 mg, 0.83 mmol) as described above for the synthesis of **7a** from **3a**. After trituration with acetone **7g** was obtained as a powder in quantitative yield. $[\alpha]_{\text{D}}^{20}$ 24 (c 1.0, DMSO); IR (neat) 3294, 2949, 1645, 1593, 1412, 1367, 964, 748 cm⁻¹; ¹H NMR (400 MHz, DMSO-d₆) δ 6.46 (s, 1H), 5.22 (s, 1H), 4.69 (d, *J* = 6.04 Hz, 1H), 3.18–3.27 (m, 1H), 3.12–3.17 (m, 1H), 1.92 (s, 3H); ¹³C NMR (100 MHz, DMSO-d₆) δ 170.8, 165.7, 160.6, 101.0, 94.5, 63.2, 33.0, 19.3; MS (ES+) Calcd. for (M + 1) C₈H₁₀NO₄S: 216.03 Obsd. 215.95.

Acknowledgements

We thank Einar Nilsson at Lund University for HRMS analysis. This work was funded by grants from the Knut and Alice Wallenberg Foundation, the foundation for technology transfer in Umeå, the Swedish Research Council and J. C. Kempe Foundation.

References

- 1 A. G. Brown, *Pure Appl. Chem.*, 1987, **59**, 475–484.
- 2 *Chemistry and Biology of β -lactam Antibiotics*, eds. R. B. Morin and M. Gorman, Academic Press: New York, 1982, Vol. 1–3.
- 3 D. Nathwani and M. Wood, *J. Drugs*, 1993, **45**, 866–894.
- 4 *The Organic Chemistry of β -Lactams*, ed. G. I. Georg, VCH, New York, 1993.

- 5 *The Chemistry of β -Lactams*, M. I. Page, Blackie Academic and Professional, New York, 1996.
- 6 C. M. Henry, *Chem. Eng. News*, 2000, **78**, 41.
- 7 C. Walsh, *Nature*, 2000, **406**, 775–781.
- 8 C. Stephens and L. Shapiro, *Chem. Biol.*, 1997, **4**, 637–641.
- 9 S. J. Hultgren, *Escherichia Coli Salmonella typhimurium*, 1996, 2730.
- 10 S. J. Hultgren, S. Abraham, M. Caparon, P. Falk, J. W. Stgeme and S. Normark, *Cell*, 1993, **73**, 887–901.
- 11 S. Langermann, S. Palaszynski, M. Barnhart, G. Auguste, J. S. Pinkner, J. Burlein, P. Barren, S. Koenig, S. Leath, C. H. Jones and S. J. Hultgren, *Science (Washington, D. C.)*, 1997, **276**, 607–611.
- 12 J. A. Roberts, B.-I. Marklund, D. Ilver, D. Haslam, M. B. Kaack, G. Baskin, M. Louis, R. Moellby, J. Winberg and S. Normark, *Proc. Natl. Acad. Sci. U. S. A.*, 1994, **91**, 11889–11893.
- 13 D. L. Hung, S. D. Knight, R. M. Woods, J. S. Pinkner and S. J. Hultgren, *Embo J.*, 1996, **15**, 3792–3805.
- 14 K. F. Karlsson, B. Walse, T. Drakenberg, S. Roy, K. E. Bergquist, J. S. Pinkner, S. J. Hultgren and J. Kihlberg, *Bioorg. Med. Chem.*, 1998, **6**, 2085–2101.
- 15 M. Pellicchia, P. Sebbel, U. Hermanns, K. Wuthrich and R. Glockshuber, *Nat. Struct. Biol.*, 1999, **6**, 336–339.
- 16 M. J. Kuehn, D. J. Ogg, J. Kihlberg, L. N. Slonim, K. Flemmer, T. Bergfors and S. J. Hultgren, *Science*, 1993, **262**, 1234–1241.
- 17 G. E. Soto, K. W. Dodson, D. Ogg, C. Liu, J. Heuser, S. Knight, J. Kihlberg, C. H. Jones and S. J. Hultgren, *Embo J.*, 1998, **17**, 6155–6167.
- 18 H. Emtenas, G. Soto, S. J. Hultgren, G. R. Marshall and F. Almqvist, *Org. Lett.*, 2000, **2**, 2065–2067.
- 19 A. Svensson, A. Larsson, H. Emtenas, M. Hedenstrom, T. Fex, S. J. Hultgren, J. S. Pinkner, F. Almqvist and J. Kihlberg, *ChemBioChem*, 2001, **2**, 915–918.
- 20 H. Emtenas, K. Ahlin, J. S. Pinkner, S. J. Hultgren and F. Almqvist, *J. Comb. Chem.*, 2002, **4**, 630–639.
- 21 J. Walker, *J. Chem. Soc., C*, 1968, 1522–1526.
- 22 C. J. Salomon, E. G. Mata and O. A. Mascaretti, *J. Org. Chem.*, 1994, **59**, 7259–7266.
- 23 E. G. Mata and O. A. Mascaretti, *Tetrahedron Lett.*, 1988, **29**, 6893–6896.
- 24 E. Alvarez, T. Cuvigny, C. H. Dupenhoat and M. Julia, *Tetrahedron*, 1988, **44**, 119–126.
- 25 M. Ohno, Y. Ito, M. Arita, T. Shibata, K. Adachi and H. Sawai, *Tetrahedron*, 1984, **40**, 145–152.
- 26 T. Tsuji, T. Kataoka, M. Yoshioka, Y. Sendo, Y. Nishitani, S. Hirai, T. Maeda and W. Nagata, *Tetrahedron Lett.*, 1979, 2793–2796.
- 27 L. Zervas and I. Photaki, *J. Am. Chem. Soc.*, 1962, **84**, 3887–3897.
- 28 F. Almqvist, D. Guillaume, S. J. Hultgren and G. R. Marshall, *Tetrahedron Lett.*, 1998, **39**, 2293–2294.
- 29 W. H. Hartung and R. Simonoff, *Org. React.*, 1953, **VII**, 263–326.
- 30 T. Kumagai, S. Tamai, T. Abe, H. Matsunaga, K. Hayashi, I. Kishi, M. Shiro and Y. Nagao, *J. Org. Chem.*, 1998, **63**, 8145–8149.
- 31 S. R. Lammert, A. I. Ellis, R. R. Chauvette and S. Kukolja, *J. Org. Chem.*, 1978, **43**, 1243–1244.
- 32 T. W. Greene and P. G. M. Wuts *Protective Groups in Organic Synthesis. 3rd Edn*, John Wiley & Sons, New York, 1999.
- 33 K. Kamata, I. Agata and A. I. Meyers, *J. Org. Chem.*, 1998, **63**, 3113–3116.
- 34 P. Braun, H. Waldmann and H. Kunz, *Synlett*, 1992, 39–40.
- 35 P. Braun, H. Waldmann, W. Vogt and H. Kunz, *Synlett*, 1990, 105–107.
- 36 D. Sebastian and H. Waldmann, *Tetrahedron Lett.*, 1997, **38**, 2927–2930.
- 37 Y. Fukase, K. Kukase and S. Kusumoto, *Tetrahedron Lett.*, 1999, **40**, 1169–1170.